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Abstract
Background: In a previous study carried out by our group, the genotyping of 36 microsatellite
markers from within a narrow interval of chromosome 6p12.3-q13 generated evidence for linkage
and for association to female hip osteoarthritis (OA), with the most compelling association found
for a marker within intron 1 of the bone morphogenetic protein 5 gene (BMP5). In this study, we
aimed to further categorize the association of variants within intron 1 of BMP5 with OA through
an expanded genetic association study of the intron and subsequent functional analysis of associated
polymorphisms.
Methods: We genotyped 18 common polymorphisms including 8 microsatellites and 9 single
nucleotide polymorphisms (SNPs) and 1 insertion/deletion (INDEL) from within highly conserved
regions between human and mouse within intron 1 of BMP5. These markers were then tested for
association to OA by a two-stage approach in which the polymorphisms were initially genotyped
in a case-control cohort comprising 361 individuals with associated polymorphisms (P ≤ 0.05) then
genotyped in a second case-control cohort comprising 1185 individuals.
Results: Two BMP5 intron 1 polymorphisms demonstrated association in the combined case-
control cohort of 1546 individuals (765 cases and 781 controls): microsatellite D6S1276 (P = 0.018)
and SNP rs921126 (P = 0.013). Functional analyses in osteoblastic, chondrocytic, and adipocytic cell
lines indicated that allelic variants of D6S1276 have significant effects on the transcriptional activity
of the BMP5 promoter in vitro.
Conclusion: Variability in gene expression of BMP5 may be an important contributor to OA
genetic susceptibility.
Background
Osteoarthritis (OA, MIM 165720) is the most common
musculoskeletal disorder in developed countries [1].
Pathologically, OA is characterized by the focal degenera-
tion of the smooth articular cartilage in any of the syno-
vial joints of the body with the hand, spine, knee, and hip
the most frequently affected joint sites [2]. In addition to
cartilage damage, OA is associated with a variety of
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changes in other joint tissues, such as new bone formation
at the joint margins (osteophytes), subchondral bone
sclerosis, and joint capsule thickening, with effects also
seen in the ligaments and peri-articular muscles and ten-
dons [2,3].
Although the underlying molecular mechanisms for dis-
ease initiation and progression are still not yet fully under-
stood, epidemiological and population-based cohort
studies have evidenced a significant genetic component to
OA susceptibility [4]. Genome-wide linkage scans and
large-scale association studies have had some success in
unravelling the genetic architecture underlying OA with
the identification of a number of susceptibility genes
[5,6]. These efforts and subsequent replication studies,
however, have done more to highlight the complex nature
of OA genetic susceptibility whereby sex-specific, joint-
specific, and population-specific genetic predispositions
have been shown to exist [5,7].
In a previous study carried out by our group, the genotyp-
ing of 36 microsatellite markers from within a narrow
interval of chromosome 6p12.3-q13 generated evidence
for linkage (P = 0.000001) and for association (P = 0.007)
to female hip OA, with the most compelling association
observed for marker D6S1276 located within intron 1 of
the bone morphogenetic protein 5 gene (BMP5) (MIM,
112265) [8]. BMP5 is a member of the TGF-β superfamily
of secreted proteins whose family members are involved
in synovial joint development and joint tissue homeosta-
sis [9]. Polymorphisms located within the transcribed
region of BMP5 and within its proximal promoter had
previously been excluded for association with OA [10], so
our association to intron 1 of BMP5 was unlikely to be
explicated by linkage disequilibrium (LD) between
D6S1276 and polymorphism/s within the coding region
or promoter of the gene. There is increasing evidence,
however, that polymorphisms in regulatory elements
involved in gene transcription play an important role in
conferring susceptibility to complex disease traits [11].
Thus, it seems plausible that the OA susceptibility
mapped to intron 1 of BMP5 may be due to polymor-
phisms in cis-regulatory elements that act by quantita-
tively altering gene expression as opposed to amino acid
substitutions that qualitatively alter the structure of the
encoded protein.
In the present study, we aimed to further categorize the
association of variants within intron 1 of BMP5  with
female hip OA through an expanded genetic association
study of the intron. We increased the number of polymor-
phic markers within intron 1 to include additional micro-
satellite markers as well as single nucleotide
polymorphisms (SNPs) and insertion/deletions (INDELs)
from within areas of high sequence conservation between
human and mouse, as inter-species comparisons have
generally proven successful in identifying functional non-
coding elements in the human genome [12]. Through this
analysis, we identified a SNP and a functional microsatel-
lite associated with OA and show that allelic variants of
the microsatellite are responsible for altered transcrip-
tional activity of the BMP5 promoter, which implies that




Female hip OA cases were ascertained through the Nuff-
ield Orthopaedic Centre in Oxford, UK based on inclu-
sion criteria of symptoms of primary OA sufficiently
severe to require total hip replacement (THR). All cases
had pain with rest and night symptoms for more than 6
months duration. The radiological stage of the disease was
Kellgren-Lawrence grade 2 or more in all cases with over
90% of cases being grade 3 or 4. Inflammatory arthritis
(rheumatoid, polyarthritic, or autoimmune disease) was
excluded, as was post-traumatic or post-septic arthritis.
No cases suggestive of skeletal dysplasia or developmental
dysplasia were included. The average age of the cases at
THR was 64 years with an age range of 58-84 years. For the
case-control investigation, a two-stage association analy-
sis was performed.
For case-control cohort 1 (CCC1), 146 female hip OA
cases that were the probands from the female families
used in our original linkage analysis as well as the 215 age-
matched female controls from that study were analyzed
[8]. For case-control cohort 2 (CCC2), an additional 619
female hip OA cases and 566 female controls were ana-
lyzed. The controls of CCC2 had an unknown OA status
and were not age-matched with the cases. All together,
765 unrelated female hip OA cases and 781 controls were
recruited for this study. All cases and all controls were UK
Caucasians. Ethical approval for this study was obtained
from the Central Oxford Research Ethics Committee.
Case-control association analysis
For the case-control association analysis, genomic DNA
was extracted from whole blood samples using standard
methods. Microsatellites were PCR amplified and hybrid-
ized with fluorescently-labelled primers. Primer
sequences and PCR conditions are available from the
authors. The fluorescently-labelled products were sepa-
rated and visualized using an Applied Biosystems 3100
Genetic Analyzer (Applied Biosystems). Microsatellite
genotypes were determined using GeneMapper 3.5 soft-
ware (Applied Biosystems). The SNPs and INDEL were
genotyped by PCR-restriction fragment length polymor-
phism (RFLP) analysis with the digestion products elec-
trophoresed through 3% agarose gels, stained withBMC Medical Genetics 2009, 10:141 http://www.biomedcentral.com/1471-2350/10/141
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ethidium bromide, and scored following UV visualiza-
tion. For each RFLP analysis, approximately 96 individu-
als were sequenced to ensure correct genotyping in the
RFLP assay. Primer sequences, restriction enzymes, and
PCR conditions are available from the authors.
The CLUMP program was used to test each microsatellite
marker for association with female hip OA [13]. Signifi-
cance was assessed for each marker by performing 1,000
simulations to generate tables with the same marginal
totals as the original data. Empirical P  values were
obtained by counting the number of times the χ2 value of
the real data was achieved by the simulated tables.
CLUMP calculates 4 statistics: T1-T4. T1 is a standard con-
tingency table χ2, T2 is a χ2 calculated after collapsing
together alleles with a small expected value (< 0.05), T3 is
the largest 2 × 2 χ2 in which each allele is compared in
turn with the rest grouped together, and T4 is the largest 2
× 2 χ2 in which alleles demonstrating a frequency differ-
ence between cases and controls are clumped together and
compared with the remainder. For SNPs and INDELs,
allele distributions in cases and controls were compared
using standard χ2 analysis-of-contingency tables. Hardy-
Weinberg equilibrium for the distribution of genotypes
was confirmed for these data using standard χ2 analysis-
of-contingency tables. Odds ratios (ORs) were calculated
with 95% confidence intervals (CIs). Frequencies of mul-
tilocus haplotypes were estimated with EH-PLUS [14],
and these haplotypes were tested for association with
female hip OA using the CLUMPHAP program [15],
which is an extension of the basic methodology of the
CLUMP program. CLUMPHAP works by collapsing simi-
lar haplotypes together into two groups to obtain the larg-
est χ2 statistic from which an empirical P-value is obtained
by permutation.
Construction of luciferase reporter plasmids
To generate constructs for use in luciferase reporter gene
assays, a 1,311 bp fragment of genomic DNA correspond-
ing to the BMP5 proximal promoter (-1783 to -472 with
respect to the translation start site of BMP5) was PCR
amplified using gene-specific primers containing either a
KpnI (forward primer) or a NheI (reverse primer) restric-
tion site at the 5' end of the primer. The source of this
genomic DNA was one of the individuals used in our
study. Primer sequences can be found in Additional file 1,
Table S1. After PCR amplification and double digestion
with KpnI and NheI restriction enzymes, the KpnI-NheI
promoter fragment was purified using the QIAquick PCR
purification kit (Qiagen). This fragment was then cloned
into the KpnI/NheI sites of the pGL3-Basic luciferase
reporter vector (Promega) using the Clonables Ligation/
Transformation kit (Novagen) to create the Promoter-
Luciferase construct (Additional file 1, Figure S1). Plasmid
DNA used for transfections was isolated from positive
clones using the GenElute HP Plasmid MidiPrep Kit
(Sigma) and sequenced to ensure that the plasmid con-
tained the correct nucleotide sequence.
PCR primers encompassing intronic polymorphisms
D6S1276, rs921126, and rs17734678 were designed with
the forward primer containing a NheI restriction site and
the reverse primer containing a HindIII restriction site at
the 5' end of the primers. Primer sequences can be found
in Additional file 1, Table S1. Genomic DNA from a case
or a control containing the allele of interest was PCR
amplified, double digested with restriction enzymes NheI
and HindIII, purified, and cloned into the KpnI/HindIII
sites of the Promoter-Luciferase construct (Additional file
1, Figure S1). These constructs were isolated and
sequenced to ensure the correct nucleotide sequence had
been cloned. Site-directed mutations of the DS1276
clones F-I and F-II were performed with the QuikChange
II Site-Directed Mutagenesis kit (Stratagene) following the
manufacturer's instructions. Primers used for the muta-
genesis reaction were designed with the QuickChange
Primer Design Program http://www.stratagene.com/
qcprimerdesign/. Primer sequences can be found in Addi-
tional file 1, Table S2. Mutated clones were sequenced to
verify the appropriate mutations had been made.
Cell culture and luciferase assay
All cells were maintained at 37°C in a humidified 5%
CO2 incubator. MG63 cells (human osteosarcoma) and
CH8 cells (human articular chondrocytes) [16] were cul-
tured in Dulbecco's modified Eagle medium (DMEM)
(Cambrex) supplemented with 10% fetal calf serum
(FCS). CH8 cells were maintained on type-I collagen
coated culture dishes (BD Biosciences). SW872 cells
(human liposarcoma) were cultured in DMEM/F-12 (3:1)
(Cambrex) with 5% FCS. Cells were seeded at a density of
approximately 3 × 105 cells per well of a 6-well cluster
plate (Appleton Woods) 24 hours before transfection.
CH8 cells were plated in type-I collagen coated 6-well
plates (BD Biosciences). Using the GeneJuice transfection
reagent (Novagen), cells were transfected with 1 μg of the
luciferase reporter construct and 1 μg of pSV-β-galactosi-
dase control vector (Promega) as an internal control to
normalize for transfection efficiency. Twenty-four hours
after transfection, the transfection mixture was removed
and replaced with complete growth medium. After an
additional 24 hours, the cells were washed once with
phosphate-buffered saline (PBS) and lysed with 250 μl of
1X Reporter Lysis Buffer (Promega) per well.
Cellular extracts were prepared and 20 μl of cell lysate was
assayed for luciferase activity with the Luciferase Assay
System (Promega) using a GloMax 20/20 Luminometer
(Promega). β-galactosidase activity was measured with a
spectrophotometric assay using 10 μl of the same cellBMC Medical Genetics 2009, 10:141 http://www.biomedcentral.com/1471-2350/10/141
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lysate and 150 μl of 2-nitrophenyl β-D-galactopyranoside
(ONPG) solution (2.9 mM ONPG, 1 mM MgCl2, 14.1
mM β-mercaptoethanol, 82 mM Na2HPO4·2H2O, and 18
mM NaH2PO4·2H2O) as substrate. Absorbencies were
measured at 420 nm and then compared to a standard
curve of know quantities of β-galactosidase. Transfections
were performed in triplicate on at least three separate
occasions. Relative luciferase activity for each transfection
was determined by taking the ratio of luciferase activity to
β-galactosidase activity, and these data were subsequently
normalized by the mean of the relative luciferase activities
of the Promoter-Luciferase construct for each cell line. Sta-
tistical comparisons were performed with the two-tailed




Seventeen polymorphic markers within intron 1 of BMP5
(9 SNPs, 1 INDEL, and 7 microsatellites) were identified
for use in the case-control association analysis (Additional
file 1, Table S3). We focused our search for SNPs and
INDELs on areas of DNA sequence homology between
human and mouse within intron 1 of BMP5 by comparing
the 54 kb genomic region encompassing intron 1 of BMP5
with the corresponding mouse sequence using the VISTA
Genome Browser http://pipeline.lbl.gov/[17] with search
criteria of at least 70% sequence identity over at least 100
base pairs in length. Through this search, we identified 28
conserved non-coding sequences (Additional file 1, Table
S4), and within these conserved sequences, 9 common
SNPs and 1 common INDEL (minor allele frequency >
5%) were identified using the UCSC Human Genome
Browser http://genome.ucsc.edu/[18] and direct DNA
sequencing. To identify microsatellite markers within
intron 1 of BMP5 for use in the association analysis, we
searched the UCSC Human Genome Browser May 2004
human reference sequence, NCBI build 35 for simple tan-
dem repeats consisting of di-, tri-, tetra-, or pentanucle-
otide repeats. The polymorphic nature of these
microsatellites was confirmed by genotyping at least 32
Caucasian chromosomes, and microsatellites having a
heterozygosity value of 30% or greater were subsequently
included in the association study.
The 17 polymorphic markers along with the microsatellite
D6S1276 were initially genotyped in case-control cohort
1 (CCC1). Two pairs of SNPs were found to demonstrate
complete LD (pair-wise r2  = 1.0): rs17734678 with
rs921126 and rs3798818 with rs9382564 (Additional file
1, Table S5), and consequently only one of the two SNPs
from each pair was studied further in the association anal-
ysis. Of the 18 polymorphisms genotyped, 5 demon-
strated significant association (P ≤ 0.05) with female hip
OA in CCC1: microsatellite D6S1276 and SNPs rs921126,
rs1470527, rs3798821, and rs9382564 (Table 1). These 5
polymorphisms were then genotyped in case-control
cohort 2 (CCC2), with none of these polymorphisms
demonstrating association with CCC2 alone. When CCC1
and CCC2 were combined, however, D6S1276 (P = 0.018,
CLUMP T4) and rs921126 (P = 0.013; OR 1.23, 95% CI
1.04-1.47) demonstrated association with the combined
cohort, and rs1470527 showed a trend toward association
(P = 0.078) (Table 1). For the analysis of D6S1276, the T4
statistic produced the strongest evidence of association,
which was achieved by clumping together alleles B, C, E,
F, G, H, and K (Table 2). Table 2 presents the allele counts
and frequencies (%) for D6S1276 and rs921126 in CCC1,
CCC2, and the combined case-control cohort.
Haplotype analysis of D6S1276
D6S1276 is a complex tetranucleotide repeat microsatel-
lite with a backbone repeat element TCTA and three SNPs
in close proximity to the microsatellite: rs9475431,
Table 1: Association analysis of polymorphisms within intron 1 of BMP5 in CCC1, CCC2, and the combined data. 
Marker CCC1 CCC2 Combined Cohort
Microsatellite P by CLUMP SNP P by 
χ2
Microsatellite P by CLUMP SNP P by 
χ2
Microsatellite P by CLUMP SNP P by 
χ2
T1 T2 T3 T4 T1 T2 T3 T4 T1 T2 T3 T4
rs921126 0.022 0.16 0.013
rs1470527 0.044 0.41 0.078
D6S1276 0.007 0.008 0.03 0.06 0.25 0.17 0.20 0.14 0.041 0.025 0.040 0.018
rs3798821 0.004 0.74 0.23
rs9382564 0.025 0.71 0.14
P values ≤ 0.05 are highlighted in bold.BMC Medical Genetics 2009, 10:141 http://www.biomedcentral.com/1471-2350/10/141
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rs9475430, and rs9475429 (Figure 1). These three SNPs
are in complete LD with each other (pair-wise r2 = 1.0)
and in very strong LD with rs1470527 (pair-wise r2 =
0.96), one of the SNPs used in our association analysis
(Additional file 1, Table S5). The haplotype structure of
rs9475431, rs9475430, and rs9475429 was analyzed and
two common haplotypes were identified, which are
depicted as haplotype I and haplotype II in Figure 1.
Because of the tight linkage between rs1470527 and the
three SNPs proximal to D6S1276, haplotype I was tagged
by the T allele of rs1470527 and haplotype II was tagged
by the C allele of rs1470527. Haplotypes were then con-
structed between rs1470527, rs9475431, rs9475430,
rs9475429, and D6S1276 in the combined cases and con-
trols of the cohort used for our association analysis.
Through this analysis, 17 haplotypes were identified,
although only 9 had a frequency ≥ 1% (Additional file 1,
Table S6). These haplotypes were tested for association
with female hip OA using the CLUMPHAP program. From
the analysis of the BMP5 haplotype data, an empirical P-
value of 0.24 was obtained after 9999 permutations.
Analysis of allelic variation of D6S1276 on transcriptional 
regulation of BMP5
To determine if the D6S1276 alleles had any effect on the
transcriptional activity of BMP5, luciferase reporter gene
Table 2: Allele counts and allele frequencies for polymorphisms D6S1276 and rs921126 in CCC1, CCC2, and the combined case-
control cohort
Marker Allele Repeat Allele Counts (%)
CCC1 CCC2 Combined Cohort Total Chromosomes
Cases Controls Cases Controls Cases Controls
D6S1276 A (TCTA)3 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 1 (0.0)
B (TCTA)5 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.0)
C (TCTA)6 1 (0.4) 0 (0.0) 1 (0.1) 2 (0.2) 2 (0.1) 2 (0.1) 4 (0.1)
D (TCTA)7 2 (0.8) 15 (3.5) 34 (2.8) 45 (4.0) 36 (2.5) 60 (3.9) 96 (3.2)
E (TCTA)8 66 (26.0) 73 (17.2) 264 (21.9) 238 (21.4) 330 (22.6) 311 (20.2) 641 (21.4)
F (TCTA)9 41 (16.1) 83 (19.6) 241 (20.0) 200 (18.0) 282 (19.3) 283 (18.4) 565 (18.9)
G (TCTA)10 106 (41.7) 189 (44.6) 497 (40.3) 450 (40.5) 603 (41.4) 639 (41.6) 1242 (41.5)
H (TCTA)11 38 (15.0) 56 (13.2) 156 (13.0) 157 (14.1) 194 (13.3) 213 (13.9) 407 (13.6)
I (TCTA)12 0 (0.0) 7 (1.7) 7 (0.6) 17 (1.5) 7 (0.5) 24 (1.6) 31 (1.0)
J (TCTA)13 0 (0.0) 0 (0.0) 2 (0.2) 3 (0.3) 2 (0.1) 3 (0.2) 5 (0.2)
K (TCTA)15 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.0)
rs921126 A ---- 81 (27.9) 87 (20.2) 333 (26.9) 272 (24.3) 414 (27.1) 359 (23.1) 773 (25.1)
G ---- 209 (72.1) 343 (79.8) 907 (73.1) 846 (75.7) 1116 (72.9) 1189 (76.9) 2305 (74.9)
Genomic structure of the BMP5 gene Figure 1
Genomic structure of the BMP5 gene. The exons are represented by boxes with black fields depicting coding regions and 
white fields representing the untranslated regions. Solid lines represent introns and intergenic regions. The positions of 
rs9475431 (1), D6S1276 (2), rs9475430 (3), and rs9475429 (4) are shown with flanking sequence within intron 1 of BMP5 along 
with the two common haplotypes comprised of rs9475431, rs9475430, rs9475429: haplotype I (TTT) and haplotype II (GCA).BMC Medical Genetics 2009, 10:141 http://www.biomedcentral.com/1471-2350/10/141
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assays were performed. Alleles with a frequency ≥ 1% (D,
E, F, G, H, I) from Table 2 were chosen, and for these alle-
les, the two haplotypic forms were analyzed. A 1.311 kb
stretch of BMP5 that had previously been shown to have
promoter activity [19] was first subcloned into the pGL3-
Basic vector upstream of the luciferase gene to create the
BMP5 Promoter-Luciferase construct. This construct was
found to have significant promoter activity compared to
the pGL3-Basic vector in all of the cell lines analyzed
(Additional file 1, Figure S2). The various haplotypes of
D6S1276 and SNPs rs9475431, rs9475430, and
rs9475429 were then subcloned into the BMP5 Promoter-
Luciferase construct and transiently transfected into
MG63 (human osteosarcoma), CH8 (human articular
chondrocytes), and SW872 (human liposarcoma) cells
(Figure 2). This analysis demonstrated that not only is
D6S1276 a functional microsatellite, but also that there is
a significant amount of inter-allelic, intra-allelic, and cell-
specific difference in the ability of these alleles to modify
transcriptional activity of the BMP5 promoter.
A variety of effects on transcriptional activity mediated by
the various D6S1276 haplotypes was observed (Figure 2).
A number of consistencies across the cell lines were iden-
tified with haplotype II-I ((TCTA)12) showing one of the
lower luciferase activities in all of the cell lines and haplo-
type I-H ((TCTA)11) showing one of the higher luciferase
activities in all of the cell lines. There were a number of
instances, however, where the transcriptional activity of a
particular allele was specific to a specific cell-type. For
example, haplotype I of the I allele ((TCTA)12) showed a
20% enhancement of luciferase activity relative to the pro-
moter-only vector in MG63 cells but a 40% repression in
CH8 cells and an 80% repression in SW872 cells. Addi-
tionally, some alleles of D6S1276 demonstrated a signifi-
cant difference in luciferase activity between haplotype I
and haplotype II in some cell-lines but not in others. For
example, haplotypes I and II of D6S1276 alleles D
((TCTA)7) and G ((TCTA)10) showed significant differ-
ences in luciferase activity (P ≤ 0.05) in CH8 and SW872
cells but not in MG63 cells, while haplotypes I and II of
D6S1276 allele E ((TCTA)8) showed significant differ-
ences in luciferase activity in MG63 and CH8 cells but not
in SW872 cells. Moreover, the D6S1276 constructs
seemed to mediate an increased repression of transcrip-
tion form the BMP5 promoter in SW872 cells relative to
the other cell lines (Figure 2), although the BMP5 Pro-
moter-Luciferase construct showed the strongest induc-
tion of luciferase activity in this cell line (Additional file 1,
Figure S2).
This study also allowed for investigation of differences in
luciferase activity between haplotypes I and II while hold-
ing the length of the allele constant. Figure 2 shows that
there is a consistent trend for significantly repressed luci-
ferase activity from constructs carrying haplotype II rela-
tive to haplotype I for each D6S1276 allele with as much
as a 4-fold repression for haplotype II relative to haplo-
type I as seen for the I allele ((TCTA)12) in MG63 cells (P
= 4.6 × 10-7). To discern which SNP/s were responsible for
the difference in transcriptional activity between haplo-
type I and II, each of the three SNPs were systematically
mutated with site-directed mutagenesis to create all possi-
ble haplotypic combinations of rs9475431, rs9475430,
and rs9475429 while holding the number of TCTA
repeats constant at 9 (F allele of D6S1276). The mutated
vectors were then transiently transfected into MG63, CH8,
and SW872 cells and assayed for luciferase activity (Addi-
tional file 1, Figure S3). To determine the functional con-
tribution of each of the three SNPs, the mean luciferase
activities of the haplotypes carrying either allele for each
SNP were compared. The mean luciferase activities of hap-
lotypes containing the T allele of rs9475429 were 1.3-fold
higher than the activities of haplotypes containing the A
allele in MG63 cells (P = 2.4 × 10-3) (Figure 3). There was
no statistically significant difference, however, in the luci-
ferase activities for haplotypes carrying the T allele or the
C allele of rs9475430 or for haplotypes carrying the T
allele or the G allele of rs9475431. Similar results were
obtained in CH8 cells and in SW872 cells (Additional file
1, Figure S4).
Functional analysis of rs921126 and rs17734678
To investigate whether the associated SNPs rs921126 and
rs17734678 generated any allelic differences in the tran-
scriptional regulation of BMP5, fragments of genomic
DNA containing the alleles of these SNPs were subcloned
into the BMP5 Promoter-Luciferase construct and trans-
fected in parallel into MG63, CH8, and SW872 cells. No
allelic difference in luciferase activity for rs921126 or
rs17734678 was observed in these three cell lines (data
not shown). LD mapping of CEPH data using Haploview
[20] and the Human HapMap release 21 revealed that
these SNPs lie in an LD block of approximately 64 kb, and
that within this interval there are at least 28 other SNPs
with a pair-wise r2 ≥ 0.5.
Discussion
Based on a previous study demonstrating association of a
microsatellite marker within intron 1 of BMP5  with
female hip OA [8], we performed an expanded genetic
study of the intron. Association of microsatellite D6S1276
with female hip OA was confirmed and the results
described here demonstrated significant variability in the
ability of different D6S1276 alleles to modulate the tran-
scriptional activity of the BMP5 promoter in vitro. Associ-
ation with female hip OA was also observed for two SNPs
showing perfect LD: rs921126 and rs17734678. No signif-
icant allelic effect on gene transcription was discovered for
either SNP, however, which suggests that these SNPs areBMC Medical Genetics 2009, 10:141 http://www.biomedcentral.com/1471-2350/10/141
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Effect of microsatellite D6S1276 polymorphism on BMP5 promoter activity Figure 2
Effect of microsatellite D6S1276 polymorphism on BMP5 promoter activity. Luciferase reporter assays of the 
D6S1276 constructs were performed in MG63 (A), CH8 (B), and SW872 cells (C). Transcriptional activities are given as a per-
centage of the activity of the Promoter-Luciferase construct for each cell line. Data shown are the mean ± SD of at least 3 
experiments done in triplicate. Black bars indicate results for haplotype I (rs9475431 T, rs9475430 T, and rs9475429 T). 
Checked bars indicate results for haplotype II (rs9475431 G, rs9475430 C, and rs9475429 A). *P < 0.05, ** P < 0.01, *** P < 
0.005, **** P < 1.0 × 10-6, NS is not significant (Student's t-test).BMC Medical Genetics 2009, 10:141 http://www.biomedcentral.com/1471-2350/10/141
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not the causal variants but are marking an LD block
within which the causal variant/s is likely to reside.
For this study, the CLUMP program [13] was used to com-
pare microsatellite allele frequencies between OA cases
and controls. For association analyses, it is recommended
that either test statistic T1 or T4 is used as these are
reported to be the most powerful and least likely to lose
information about differences between cases and con-
trols. For our analysis of D6S1276, the T4 statistic pro-
duced the strongest evidence of association, which
suggests that OA susceptibility is mediated by multiple
D6S1276 alleles as T4 is calculated to maximize the χ2
value by comparing a variable number of alleles against
the rest in all possible 2 × 2 tables. The putative involve-
ment of multiple D6S1276 alleles in OA susceptibility is
further strengthened by our in vitro data that revealed
allele-specific control of cis-regulation. Additionally, asso-
ciation analysis of rs9475429 (via rs1470527) and haplo-
type analysis of D6S1276 and rs9475429 showed no
significant association, suggesting that although
rs9475429 is functional, OA susceptibility mediated by
D6S1276 has more to do with the particular size of the
allele than its haplotypic composition.
The luciferase reporter assays described here demon-
strated that D6S1276 and its flanking sequences mediated
considerable inter-allelic, intra-allelic and cell-specific
variability on the transcriptional activity of the BMP5 pro-
moter. Inter-allelic differences have been noted for a
number of other intronic microsatellites [21-23]. For
example, a TCAT microsatellite within intron 1 of the
tyrosine hydroxylase gene was found to mediate quantita-
tive effects on gene expression due to allelic variations in
affinity for nuclear proteins with longer repeat alleles
showing increased protein interaction when compared
with shorter repeat alleles [21]. Thus, a possible mecha-
nism for inter-allelic differences in the transcriptional
activity of various D6S1276 alleles could be differential
affinity for nuclear factors between different size D6S1276
alleles. Indeed, D6S1276 contains a consensus-binding
site for proteins of the GATA family of transcription fac-
tors with the consensus WGATAR corresponding to the
complementary strand of D6S1276 tAGATAGa [24].
The bone morphogenetic proteins (BMPs) constitute a
subfamily within the TGF-β superfamily of secreted sign-
aling molecules. Initially discovered as promoters of bone
growth and formation, BMPs are now known to be key
participants in the morphogenesis of a variety of verte-
brate tissues and organs with a well-defined role in the dif-
ferentiation of chondrocytes through promotion of cell
proliferation and matrix synthesis [25,26]. In particular,
BMP5 has been shown to play an important role in the
regulation of ovarian development [27], cardiac develop-
ment [28], and limb bud development [29] with a well-
defined role in the differentiation of chondrocytes
through promotion of cell proliferation and matrix syn-
thesis [30,31].
In a previous study, we characterized the differential
allelic expression (DAE) of the BMP5 gene in a variety of
mesenchymal-derived tissues [32]. We discovered that not
only is DAE of BMP5 common, but that there is also sig-
nificant variability both to the existence and extent of
allelic imbalance in the tissues within an individual, sug-
gesting that BMP5 expression is regulated by a complex
network of tissue-specific control elements. Indeed, previ-
ous work on the expression of mouse Bmp5 demonstrated
an extensive transcriptional control network regulating
the expression of mouse Bmp5 with a number of tissue-
specific cis-acting regulatory sequences [33,34]. These reg-
ulatory sequences were not only shown to regulate Bmp5
expression in distinct skeletal structures but to also govern
expression in highly discrete growth domains within these
tissues [35]. Based on the results of our current study, it is
plausible then that D6S1276 contributes to both the
allelic imbalance and the context-specific control in
human BMP5 expression, as we observed a number of
allele-specific and cell-specific expression patterns in the
mesenchymal-derived cell lines that were used in this
study.
Conclusions
The TGF-β signaling pathway has received much attention
in OA genetic susceptibility recently with reports of asso-
ciation to functional variants in the ASPN gene (encoding
asporin, a negative regulator of TGF-β signaling) [36-38]
SNP comparison of rs9475431, rs9475430, and rs9475429  on BMP5 promoter activity Figure 3
SNP comparison of rs9475431, rs9475430, and 
rs9475429 on BMP5 promoter activity. Luciferase 
reporter assays comparing the mean transcriptional activities 
of haplotypes containing the T allele of rs9475431 and haplo-
types containing the G allele, haplotypes containing the T 
allele of rs9475430 and haplotypes containing the C allele, 
and haplotypes containing the T allele of rs9475429 and hap-
lotypes containing the A allele were performed in MG63 
cells. Data shown are the mean ± SD. * P = 2.4 × 10-3. NS is 
not significant.BMC Medical Genetics 2009, 10:141 http://www.biomedcentral.com/1471-2350/10/141
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and the GDF5 gene (encoding GDF5, a member of the
BMP family of signaling molecules) [39-41]. Moreover,
microarray analysis of RNA extracted from bone samples
of OA cases and non-OA controls demonstrated altered
expression of a number of TGF-β related genes in the OA
samples including TGFB1  (encoding TGF-β1),  BMP5,
INHBA (encoding activin βA, a TGF-β superfamily signal-
ing molecule), and FST  (encoding follistatin, a TGF-β/
BMP antagonist), further strengthening the potential role
of TGF-β related genes in OA susceptibility [42]. These
studies in combination with our present BMP5 study sug-
gest that subtle, quantitative alterations in TGF-β related
signaling realized through polymorphisms affecting tran-
scription factor binding and/or downstream interactions
with binding partners is a major contributor to OA genetic
susceptibility. Further interrogation of the TGF-β signal-
ing pathway has the potential to not only reveal a large
subset of genes likely to increase susceptibility to OA but
also to reveal common mediators involved in transducing
the signal such as transcription factors, co-activators, co-
repressors, and downstream effectors that could serve as
targets for therapeutic interventions.
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